CORRIGENDUM

JAK2-V617F activating mutation in acute myeloid leukemia: prognostic impact and association with other molecular markers

C Vicente, I Vázquez, N Marcotegui, A Conchillo, C Carranza, G Rivell, E Bandrés, I Cristobal, I Lahortiga, MJ Calasanz and MD Otero

Leukemia (2007) 21, 2576; doi:10.1038/sj.leu.2405004

Correction to: *Leukemia* (2007) 21, 2386–2390.
 doi:10.1038/sj.leu.2404812

The above paper includes a literature research on published papers on JAK2 and AML. After the above article was sent for its publication, a manuscript including the screening of 959 AML patients for the presence of JAK-V617F mutations was published in *Haematologica*, and the results of this article were not included in the revision.

Therefore, Table 2 (Review of the literature of the cases reported with AML and JAK2-V617F) should include the

following data of Illmer *et al.*: No. cases analyzed: 959; No. cases mutated: 10 (1%); Diagnosis of mutated cases when subtypes specified: 9/785 AML *de novo* (1.1%), 2 with t(8;21) and 3 with inv(16); and 1/34 AML pre-existing MDS (2.9%).

Reference: Illmer T, Schaich M, Ehninger G, Thiede C. Tyrosine kinase mutations of JAK2 are rare events in AML but influence prognosis of patients with CBF-leukemias. *Haematologica* 2007; 92:137–138.

The authors apologize for any inconvenience caused. Please see below the complete table:

Table 2 Review of the literature of the cases reported with AML and JAK2-V617F

Reference	No. of cases analyzed	No. of cases mutated	Diagnosis of mutated cases when subtypes specified
Levine <i>et al.</i> (2005)	222	4 (1.8%)	1 AML <i>de novo</i> , 3 AML pre-existing MPD
Jones <i>et al.</i> (2005)	35	No mutations detected	
Jelinek <i>et al.</i> (2005)	53	7 (28%)	2/11 <i>de novo</i> , AML-M7 (18%) 5/14 AML pre-existing MPD (36%)
Scott <i>et al.</i> (2005)	90	5 (5.5%)	
Lee <i>et al.</i> (2006)	113	3 (2.7%)	3/113 AML <i>de novo</i> (2.7%): – 2 V617F / 12 AML with t(8;21) (16.6%); – 1 K607N / 15 AML without maturation (6.6%)
Fröhling <i>et al.</i> (2006)	152	6 (3.7%)	1/152 AML <i>de novo</i> M5, M6 and M7 (0.7%): 1/53 AML-M6 (6.6%) 5/7 AML pre-existing MPD (71%) 7/7 AML pre-existing MPD (100%)
Suzuki <i>et al.</i> (2006)	72	7 (9.7%)	3/149 AML <i>de novo</i> (2%): 1 M2; 1/12 M6 (8.3%); 1/24 M7 (4.1%)
Steensma <i>et al.</i> (2006)	162	13 (8%)	10/13 AML pre-existing MPD (76.9%) 4/64 AML with t(8;21) (6.2%)
Dohner <i>et al.</i> (2006)	163	4 (9.7%)	2/3 t-AML with t(8;21) (66.6%)
Schnittger <i>et al.</i> (2007)	24	2 (8%)	9/785 AML <i>de novo</i> (1.1%), 2 with t(8;21) and 3 with inv(16); and 1/34 AML pre-existing MDS (2.9%)
Illmer <i>et al.</i> (2007)	959	10 (1%)	